Literature DB >> 11531950

Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells.

J T Voeten1, G F Rimmelzwaan, N J Nieuwkoop, R A Fouchier, A D Osterhaus.   

Abstract

In general, exogenous proteins are processed by antigen-presenting cells in the endosomes for major histocompatibility complex (MHC) class II presentation to CD4+ T cells, while proteins synthesized endogenously are processed in the cytoplasm for MHC class I presentation to CD8+ T cells. However, it is recognized that exogenous proteins can be processed for MHC class I presentation also, and evidence in favour of alternatives to the conventional MHC class I processing and presentation pathway is accumulating. Here, we show that exogenous recombinant influenza A virus nucleoprotein (rNP) is processed for MHC class I presentation to CD8+ cytotoxic T lymphocytes (CTL) by EBV-transformed, B-lymphoblastoid cell lines (B-LCL). Processing of rNP for HLA-B27-associated presentation seemed to follow the conventional MHC class I pathway predominantly, as presentation was diminished in the presence of lactacystin and brefeldin A, but was less sensitive to chloroquine and NH4Cl. HLA-B27-associated presentation was also observed using cells lacking a functional transporter associated with antigen processing, suggesting that alternative pathways may be exploited for processing of rNP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531950      PMCID: PMC1906139          DOI: 10.1046/j.1365-2249.2001.01613.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin.

Authors:  R S Lee; E Tartour; P van der Bruggen; V Vantomme; I Joyeux; B Goud; W H Fridman; L Johannes
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

Review 2.  TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing.

Authors:  J W Yewdell; H L Snyder; I Bacik; L C Antón; Y Deng; T W Behrens; T Bachi; J R Bennink
Journal:  J Immunother       Date:  1998-03       Impact factor: 4.456

3.  Characterization of transport of newly assembled, T cell-stimulatory MHC class II-peptide complexes from MHC class II compartments to the cell surface.

Authors:  L Pond; C Watts
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

4.  Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation.

Authors:  M J Wick; J D Pfeifer
Journal:  Eur J Immunol       Date:  1996-11       Impact factor: 5.532

5.  TAP peptide transporter-independent presentation of heat-killed Sendai virus antigen on MHC class I molecules by splenic antigen-presenting cells.

Authors:  T Liu; B Chambers; A D Diehl; L Van Kaer; M Jondal; H G Ljunggren
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

6.  HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading.

Authors:  C A Peh; S R Burrows; M Barnden; R Khanna; P Cresswell; D J Moss; J McCluskey
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

7.  TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide.

Authors:  I Bacik; J H Cox; R Anderson; J W Yewdell; J R Bennink
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

8.  Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules.

Authors:  S Daniel; V Brusic; S Caillat-Zucman; N Petrovsky; L Harrison; D Riganelli; F Sinigaglia; F Gallazzi; J Hammer; P M van Endert
Journal:  J Immunol       Date:  1998-07-15       Impact factor: 5.422

9.  Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.

Authors:  P Brossart; M J Bevan
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

10.  Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing.

Authors:  H L Snyder; I Bacík; J R Bennink; G Kearns; T W Behrens; T Bächi; M Orlowski; J W Yewdell
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

View more
  10 in total

1.  HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.

Authors:  Jodie P Goodridge; Ni Lee; Aura Burian; Chul-Woo Pyo; Scott S Tykodi; Edus H Warren; Cassian Yee; Stanley R Riddell; Daniel E Geraghty
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

2.  T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.

Authors:  Angela Wahl; William McCoy; Fredda Schafer; Wilfried Bardet; Rico Buchli; Daved H Fremont; William H Hildebrand
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

3.  The C terminus of the nucleoprotein of influenza A virus delivers antigens transduced by Tat to the trans-golgi network and promotes an efficient presentation through HLA class I.

Authors:  Francesca Bettosini; Maria Teresa Fiorillo; Adriana Magnacca; Laura Leone; Maria Rosaria Torrisi; Rosa Sorrentino
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics.

Authors:  T Baas; C R Baskin; D L Diamond; A García-Sastre; H Bielefeldt-Ohmann; T M Tumpey; M J Thomas; V S Carter; T H Teal; N Van Hoeven; S Proll; J M Jacobs; Z R Caldwell; M A Gritsenko; R R Hukkanen; D G Camp; R D Smith; M G Katze
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

5.  The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro.

Authors:  E G M Berkhoff; M M Geelhoed-Mieras; E J Verschuren; C A van Baalen; R A Gruters; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Clin Exp Immunol       Date:  2007-02-26       Impact factor: 4.330

6.  Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes.

Authors:  A C M Boon; G de Mutsert; Y M F Graus; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro.

Authors:  E G M Berkhoff; A C M Boon; N J Nieuwkoop; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  HLA class I molecules consistently present internal influenza epitopes.

Authors:  Angela Wahl; Fredda Schafer; Wilfried Bardet; Rico Buchli; Gillian M Air; William H Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  CD4+ T helper cells use CD154-CD40 interactions to counteract T reg cell-mediated suppression of CD8+ T cell responses to influenza.

Authors:  André Ballesteros-Tato; Beatriz León; Frances E Lund; Troy D Randall
Journal:  J Exp Med       Date:  2013-07-08       Impact factor: 14.307

10.  Potential Role of Rainbow Trout Erythrocytes as Mediators in the Immune Response Induced by a DNA Vaccine in Fish.

Authors:  Sara Puente-Marin; Ivan Nombela; Veronica Chico; Sergio Ciordia; Maria Carmen Mena; Luis Garcia Perez; Julio Coll; Maria Del Mar Ortega-Villaizan
Journal:  Vaccines (Basel)       Date:  2019-07-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.